NATCOPHARM

Natco Pharma Share Price

₹1,421.95 +12.95 (0.92%)

05 Nov, 2024 17:19

SIP TrendupStart SIP in NATCOPHARM

Start SIP

Performance

  • Low
  • ₹1,403
  • High
  • ₹1,428
  • 52 Week Low
  • ₹729
  • 52 Week High
  • ₹1,639
  • Open Price₹1,409
  • Previous Close₹1,409
  • Volume273,870

Investment Returns

  • Over 1 Month + 5.02%
  • Over 3 Month + 3.97%
  • Over 6 Month + 37.51%
  • Over 1 Year + 91.23%
SIP Lightning

Smart Investing Starts Here Start SIP with Natco Pharma for Steady Growth!

Natco Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 25,469
  • P/B Ratio
  • 4.3
  • Average True Range
  • 45.42
  • EPS
  • 73.1
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -24.54
  • RSI
  • 52.14
  • MFI
  • 44.32

Natco Pharma Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations1,236.90964.80625.30930.501,048.30
Total Income From Operations1,236.90964.80625.30930.501,048.30
P/L Before Interest, Excpt. Items & Tax762.40437.00227.40427.00478.40
P/L Before Exceptional Items & Tax758.00432.50223.60424.00475.20
P/L After Tax from Ordinary Activities636.30349.10192.00360.20405.30
Net Profit/Loss For the Period636.30349.10192.00360.20405.30
IndicatorMar 24Mar 23
Revenue From Operations [Gross]3,548.902,340.80
Revenue From Operations [Net]3,548.902,340.80
Total Operating Revenues3,568.902,351.00
Total Revenue3,673.602,436.50
Total Expenses2,118.301,665.80
Profit/Loss Before Tax1,555.30770.70
Profit/Loss For The Period1,306.60637.10
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity1,196.40784.40
Net Cash Used In Investing Activity-960.50-436.60
Net Cash Used in Finance Activity-237.30-346.80
Net Inc/Dec In Cash And Equivalent-1.401.00
Cash And Equivalent End Of Year5.506.90
IndicatorMar 24Mar 23
Total Share Capital35.8036.50
Total Non-Current Liabilities76.10116.90
Total Current Liabilities885.60569.00
Total Capital And Liabilities6,554.005,387.90
Total Non-Current Assets3,143.602,893.20
Total Current Assets3,410.402,494.70
Total Assets6,554.005,387.90
Indicator20242023
EBIT Margin (%)43.9833.14
Return On Capital Employed (%)27.6916.17
Return On Equity (%)23.3613.54
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)312.42257.64
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations1,362.601,068.30758.601,031.401,140.50
Total Income From Operations1,362.601,068.30758.601,031.401,140.50
P/L Before Interest, Excpt. Items & Tax808.80483.80260.90443.80504.20
P/L Before Exceptional Items & Tax803.60477.60256.30439.60500.00
P/L After Tax from Ordinary Activities668.50386.30212.70369.00420.30
Net Profit/Loss For the Period668.50386.30212.70369.00420.30
IndicatorMar 24Mar 23
Revenue From Operations [Gross]3,978.802,696.90
Revenue From Operations [Net]3,978.802,696.90
Total Operating Revenues3,998.802,707.10
Total Revenue4,126.902,811.70
Total Expenses2,453.401,949.80
Profit/Loss Before Tax1,673.50861.90
Profit/Loss For The Period1,388.30715.30
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity1,211.60849.10
Net Cash Used In Investing Activity-1,032.70-477.10
Net Cash Used in Finance Activity-246.90-363.00
Net Inc/Dec In Cash And Equivalent-61.5020.80
Cash And Equivalent End Of Year70.40131.90
IndicatorMar 24Mar 23
Total Share Capital35.8036.50
Total Non-Current Liabilities80.40100.50
Total Current Liabilities972.80683.10
Total Capital And Liabilities6,906.305,657.40
Total Non-Current Assets2,882.802,657.10
Total Current Assets4,023.503,000.30
Total Assets6,906.305,657.40
Indicator20242023
EBIT Margin (%)42.3332.37
Return On Capital Employed (%)28.5217.61
Return On Equity (%)23.7114.67
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)326.99267.06

Natco Pharma Technicals

EMA & SMA

Current Price
₹1,421.95
+ 12.95 (0.92%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹1,387.21
  • 50 Day
  • ₹1,402.09
  • 100 Day
  • ₹1,345.92
  • 200 Day
  • ₹1,212.24

Resistance and Support

1412.33 Pivot Speed
  • R3 1,464.52
  • R2 1,448.23
  • R1 1,428.62
  • S1 1,392.72
  • S2 1,376.43
  • S3 1,356.82

Is Natco Pharma Worth Buying?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

NATCO Pharma Ltd. is a leading Indian pharmaceutical company specializing in generic and specialty medicines, including oncology, cardiology, and central nervous system therapies. It serves global markets with a focus on affordable and high-quality healthcare solutions. Natco Pharma has an operating revenue of Rs. 4,220.90 Cr. on a trailing 12-month basis. An annual revenue growth of 47% is outstanding, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 20% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Natco Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results & Interim Dividend
2024-08-12 Quarterly Results & Interim Dividend
2024-05-27 Audited Results
2024-02-14 Quarterly Results & Interim Dividend
2023-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
2024-02-26 INTERIM Rs.1.25 per share(62.5%)Third Interim Dividend
2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend
2023-02-21 INTERIM Rs.1.25 per share (62.5%) Third Interim Dividend

Natco Pharma F&O

Natco Pharma Shareholding Pattern

49.62%
2.37%
4.23%
17.51%
0%
22.6%
3.67%
  • NSE Symbol
  • NATCOPHARM
  • BSE Symbol
  • 524816
  • ISIN
  • INE987B01026

Natco Pharma FAQs

Natco Pharma share price is ₹1,421 As on 05 November, 2024 | 17:05

The Market Cap of Natco Pharma is ₹25468.5 Cr As on 05 November, 2024 | 17:05

The P/E ratio of Natco Pharma is 15.6 As on 05 November, 2024 | 17:05

The PB ratio of Natco Pharma is 4.3 As on 05 November, 2024 | 17:05

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form